Royalty Pharma PLC (NASDAQ:RPRX) Receives $46.00 Consensus PT from Analysts

Shares of Royalty Pharma PLC (NASDAQ:RPRX) have been assigned a consensus recommendation of “Buy” from the five ratings firms that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $46.00.

Several research firms have recently commented on RPRX. Citigroup upped their target price on Royalty Pharma from $40.00 to $42.00 and gave the company a “buy” rating in a research report on Tuesday, July 22nd. The Goldman Sachs Group assumed coverage on Royalty Pharma in a research note on Tuesday, September 30th. They issued a “buy” rating and a $42.00 price target for the company. Wall Street Zen cut Royalty Pharma from a “buy” rating to a “hold” rating in a research report on Saturday, September 13th. Morgan Stanley boosted their target price on shares of Royalty Pharma from $51.00 to $54.00 and gave the company an “overweight” rating in a research report on Thursday, July 10th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Royalty Pharma in a research report on Saturday, September 27th.

Royalty Pharma Price Performance

Shares of RPRX opened at $36.07 on Friday. The company’s 50-day moving average is $36.28 and its 200-day moving average is $34.56. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.26 and a quick ratio of 1.26. The firm has a market capitalization of $21.03 billion, a PE ratio of 20.85, a PEG ratio of 2.25 and a beta of 0.60. Royalty Pharma has a fifty-two week low of $24.05 and a fifty-two week high of $38.00.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $1.14 EPS for the quarter, beating analysts’ consensus estimates of $1.10 by $0.04. The business had revenue of $578.67 million for the quarter, compared to analyst estimates of $750.06 million. Royalty Pharma had a net margin of 44.23% and a return on equity of 25.54%. Equities analysts forecast that Royalty Pharma will post 4.49 EPS for the current year.

Royalty Pharma Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th were paid a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date was Friday, August 15th. Royalty Pharma’s dividend payout ratio (DPR) is 50.87%.

Institutional Trading of Royalty Pharma

Several large investors have recently modified their holdings of RPRX. USA Financial Formulas acquired a new position in Royalty Pharma in the second quarter valued at about $32,000. Louisbourg Investments Inc. bought a new position in Royalty Pharma in the 1st quarter valued at about $28,000. Summit Securities Group LLC acquired a new position in shares of Royalty Pharma in the 1st quarter valued at approximately $36,000. WPG Advisers LLC bought a new stake in shares of Royalty Pharma during the 1st quarter worth approximately $39,000. Finally, MassMutual Private Wealth & Trust FSB lifted its holdings in shares of Royalty Pharma by 42.1% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 1,358 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 402 shares during the period. 54.35% of the stock is owned by institutional investors and hedge funds.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.